Physician profile
Gaurav Gupta
NPI 1083808695
$168,014.92
in general payments reported to CMS, 2019-2025
21 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $27K · 2021: $22K · 2022: $30K · 2023: $23K · 2024: $19K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $26K · Travel and Lodging: $6,211 · Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,470.00 |
| Consulting Fee | $25,500.67 |
| Travel and Lodging | $6,210.69 |
| Food and Beverage | $2,041.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $74,670.74 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $32,911.27 | 2020-2024 | Terlivaz |
| Mallinckrodt Enterprises LLC | $27,117.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14,818.09 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $10,218.33 | 2025 | Empaveli |
| Veloxis Pharmaceuticals, INC. | $5,846.97 | 2019-2025 | Envarsus |
| Ani Pharmaceuticals, INC. | $1,175.00 | 2021 | |
| Aurinia Pharma U.S., INC. | $400.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $326.67 | 2024 | |
| Astellas Pharma US INC | $165.21 | 2024-2025 | Izervay |
| Akebia Therapeutics INC | $125.00 | 2024 | Auryxia, Vafseo |
| Medtronic, INC. | $88.42 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $42.00 | 2019 | |
| Microvention, INC. | $38.99 | 2024 | Web Aneurysm Embolization System |
| Exact Sciences Corporation | $24.02 | 2023 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.73 | 2025 | Jardiance |
| Amarin Pharma, INC. | $13.59 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.